Drugs / H7N3 pLAIV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03581903 | Sep 2017 → Sep 2018 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H7N3 pLAIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03581903 ↗ |
| Modality | Vaccine | “live attenuated A/H7N3 influenza virus vaccine” NCT03581903 ↗ |
| Route | Intranasal | “administered intranasally by an Accuspray device” NCT03581903 ↗ |